Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient
Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at twelve of the key indices captured in Therapy Watch data.
JAK inhibitors gaining traction for rheumatoid arthritis in EU5
The new class of JAK inhibitor therapies is making a strong impression in the European market for rheumatoid arthritis (RA), according to recent prescribing data from specialist physicians.
Our latest Therapy Watch RA study, conducted in the key EU5 countries (France, Germany, Italy, Spain and the UK), found that in the dynamic segment of the RA market – defined as patients who have started or switched onto their current RA treatment in the three months preceding inclusion in the study – the orally -administered JAK inhibitors expanded their market share across the EU5 from 3.1% in the third quarter of 2017 to 15.6% in the second quarter of 2018.
EULAR Annual European Congress of Rheumatology 2016
8-11 June 2016, London
Research Partnership is delighted to be attending the EULAR Annual European Congress of Rheumatology in June. Since its introduction in 2000, the congress has become the primary platform for exchange of scientific and clinical information in Europe. With more than 16,000 delegates from all over the world registered at the EULAR Congress 2011 in London, this year’s London Congress is hoping to surpass all previous records.
RA Perceptions infographic
HCPs predict the future of the biologics market
Findings from a recent survey of physicians across Europe has revealed that, despite stiff competition from newer biologics, biosimilars and pipeline agents, physicians expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time. Nevertheless, the anti-TNF segment is predicted to experience a strong downturn with a 19% loss in share in the same period.
RA Perceptions is a market research study which is carried out every month amongst a panel of 200 physicians across five European countries (France, Germany, Italy, Spain and the UK) and asks physicians about current and future perceptions of the RA market. These findings are from the June survey. RA Perceptions is a component of a larger ongoing patient tracking study called Therapy Watch RA, conducted by global healthcare market research specialist Research Partnership. An infographic highlights the key findings from the study.
EULAR Annual European Congress of Rheumatology 2014
Join us at EULAR Congress 2014 in Paris on Friday 13th June at 11:45 - 13:30
We are delighted to be attending and presenting at this year’s EULAR Annual European Congress of Rheumatology in Paris. The EULAR annual congress is a major event in the field of rheumatology and a great forum for scientific (both clinical and basic) educational and social exchange between healthcare professionals involved in rheumatology, patient organisations and the pharmaceutical industry. Representing the Research Partnership and more specifically, Therapy Watch, will be Director Allison Fleetwood and Associate Director Laurent Chanroux who work at our London headquarters.